Adjunctive Risperidone in Clozapine-Treated Patients

This recruitment ends on 12/31/07 

The ORP was one of the first outpatient programs to study clozapine and demonstrate it's effectiveness in an outpatient population. Though more effective than other antipsychotic medications, there is still a significant percentage of people who continue to experience debilitating symptoms, despite having had some improvement on clozapine. The purpose of the current study is to examine whether the addition of risperidone (Risperdal) to a stable, optimal dose of clozapine may decrease persistent positive symptoms and cognitive impairments.

During the protocol, subjects will be randomly assigned to receive either 4mg of Risperidone or placebo for the duration of the 12-week study. Subjects are compensated for their time with $10 per week for each week of study.

Eligibility Criteria:

• Diagnosis of schizophrenia or schizoaffective disorder
• Age 18-65
• Currently on clozapine for six months or more
• Never had previous trial of Risperidone (up to 8mg) along with clozapine for a one month period of time

Printer friendly Email this page